Evidence map›Paper›PMID 39812840›Full record

ArticleJournal of neurology2025

Patterns of Tau pathology in patients with anti-IgLON5 disease visualized by Florzolotau (18F) PET.

Siyuan Fan, Chenhao Jia, Menglin Liang, Haitao Ren, Tianhao Zhang, Qijun Li, Zhaoxia Huang, Tzu-Chen Yen, Chujun OuYang, Ruixue Cui and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Brain atrophy patterns in anti-IgLON5 disease.Brain : a journal of neurology · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Siyuan Fan *Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
Chenhao Jia *Department of Nuclear Medicine, Peking Union Medical College Hospital Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
Menglin Liang *Department of Nuclear Medicine, Peking Union Medical College Hospital Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
Haitao RenDepartment of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
Tianhao ZhangBeijing Engineering Research Center of Radiographic Techniques and Equipment, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing, China.
Qijun LiDepartment of Nuclear Medicine, Peking Union Medical College Hospital Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
Zhaoxia HuangDepartment of Nuclear Medicine, Peking Union Medical College Hospital Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
Tzu-Chen YenAPRINOIA Therapeutics Co, Ltd., Suzhou, China.
Chujun OuYangSchool of Computer Science, Xiangtan University, Xiangtan, Hunan, China.
Ruixue CuiDepartment of Nuclear Medicine, Peking Union Medical College Hospital Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China. mmdhmm@126.com.
Hongzhi GuanDepartment of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China. pumchghz@126.com.

Funding

Institute of High Energy Physics, Chinese Academy of Sciences No. E4545AU21National Natural Science Foundation of China No. 12175268National Natural Science Foundation of China No. 12205329Peking Union Medical College Hospital 2022-PUMCH-B-070Peking Union Medical College Hospital 2022-PUMCH-B-120Peking Union Medical College Hospital No. pumch201911390
6 · The paper itself

Abstract

backgroundAnti-IgLON5 disease is a rare autoimmune neurological disorder with prominent Tau protein deposits in the brainstem and hypothalamus. The aim of this study was to visualize the in vivo distribution patterns of Tau protein in patients with anti-IgLON5 disease using the second-generation Tau PET tracer, Florzolotau (18F) PET imaging.

methodsPatients diagnosed with anti-IgLON5 disease were enrolled consecutively. Age- and sex-matched healthy controls (HCs) were also enrolled. The uptake of Florzolotau (18F) and

resultsA total of 10 patients with anti-IgLON5 disease and 40 HCs were included in the study. All ten patients with anti-IgLON5 disease underwent Florzolotau (18F) PET scans, and five of them underwent

conclusionsThis study indicates distinct Tau protein deposition patterns in patients with anti-IgLON5 disease, potentially serving as imaging biomarkers.

Indexed as

Autoimmune Diseases of the Nervous SystemBrainCell Adhesion Molecules, NeuronalPositron-Emission Tomographytau ProteinsAdultAgedCarbolinesFemaleFluorodeoxyglucose F18GPI-Linked ProteinsHumansMaleMiddle AgedRadiopharmaceuticals7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indoleCarbolinesCell Adhesion Molecules, NeuronalFluorodeoxyglucose F18GPI-Linked ProteinsIgLON5 protein, humanMAPT protein, humanRadiopharmaceuticalstau Proteins18F-FDGAnti-IgLON5 diseaseFlorzolotau (18F)PET imagingTau protein

Identifiers

PMID39812840

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.